Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Socorro Alforja

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
The British Journal of Ophthalmology|May 13, 2026
Suspending vascular endothelial growth factor inhibitors in eyes with retinal vein occlusionAdrian Robert Hunt, Yohei Hashimoto, Louise O'Toole, et al.
International Journal of Molecular Sciences|October 27, 2022
Diagnostic Odyssey in an Adult Patient with Ophthalmologic Abnormalities and Hearing Loss: Contribution of RNA-Seq to the Diagnosis of a PEX1 DeficiencyGerard Muñoz-Pujol, Socorro Alforja-Castiella, Ricardo Casaroli-Marano, et al.
Plos One|January 19, 2024
Next-generation sequencing-based gene panel tests for the detection of rare variants and hypomorphic alleles associated with primary open-angle glaucomaElena Milla, Javier Laguna, Mª Socorro Alforja, et al.
Acta Ophthalmologica|May 7, 2021
Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! RegistryPierre-Henry Gabrielle, Vuong Nguyen, Catherine Creuzot-Garcher, et al.
Ophthalmology. Retina|April 19, 2024
Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion: Fight Retinal Blindness!Socorro Alforja, Adrian Hunt, Vuong Nguyen, et al.
The British Journal of Ophthalmology|January 26, 2022
Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! RegistryAdrian Robert Hunt, Vuong Nguyen, Jennifer J Arnold, et al.
Ophthalmology. Retina|November 12, 2022
Central Retinal Vein Occlusion 36-Month Outcomes with Anti-VEGF: The Fight Retinal Blindness! RegistryAdrian Hunt, Vuong Nguyen, Sanjeeb Bhandari, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|March 4, 2026
Faricimab for recalcitrant neovascular age-related macular degeneration: A real-life study following Aflibercept nonresponseCarolina Bernal-Morales, Sol Burgos Herrera, Lena Giralt, et al.
The British Journal of Ophthalmology|March 13, 2021
Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registryAdrian R Hunt, Vuong Nguyen, Catherine P Creuzot-Garcher, et al.
Frontiers in Immunology|April 18, 2024
C-reactive protein-complement factor H axis as a biomarker of activity in early and intermediate age-related macular degenerationLena Giralt, Marc Figueras-Roca, Beatriz De Luis Eguileor, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
The British Journal of Ophthalmology|May 13, 2026
Suspending vascular endothelial growth factor inhibitors in eyes with retinal vein occlusionAdrian Robert Hunt, Yohei Hashimoto, Louise O'Toole, et al.
International Journal of Molecular Sciences|October 27, 2022
Diagnostic Odyssey in an Adult Patient with Ophthalmologic Abnormalities and Hearing Loss: Contribution of RNA-Seq to the Diagnosis of a PEX1 DeficiencyGerard Muñoz-Pujol, Socorro Alforja-Castiella, Ricardo Casaroli-Marano, et al.
Plos One|January 19, 2024
Next-generation sequencing-based gene panel tests for the detection of rare variants and hypomorphic alleles associated with primary open-angle glaucomaElena Milla, Javier Laguna, Mª Socorro Alforja, et al.
Acta Ophthalmologica|May 7, 2021
Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! RegistryPierre-Henry Gabrielle, Vuong Nguyen, Catherine Creuzot-Garcher, et al.
Ophthalmology. Retina|April 19, 2024
Three-Year Outcomes of VEGF Inhibitors in Naive Branch Retinal Vein Occlusion: Fight Retinal Blindness!Socorro Alforja, Adrian Hunt, Vuong Nguyen, et al.
The British Journal of Ophthalmology|January 26, 2022
Hemiretinal vein occlusion 12-month outcomes are unique with vascular endothelial growth factor inhibitors: data from the Fight Retinal Blindness! RegistryAdrian Robert Hunt, Vuong Nguyen, Jennifer J Arnold, et al.
Ophthalmology. Retina|November 12, 2022
Central Retinal Vein Occlusion 36-Month Outcomes with Anti-VEGF: The Fight Retinal Blindness! RegistryAdrian Hunt, Vuong Nguyen, Sanjeeb Bhandari, et al.
Canadian Journal of Ophthalmology. Journal Canadien D'Ophtalmologie|March 4, 2026
Faricimab for recalcitrant neovascular age-related macular degeneration: A real-life study following Aflibercept nonresponseCarolina Bernal-Morales, Sol Burgos Herrera, Lena Giralt, et al.
The British Journal of Ophthalmology|March 13, 2021
Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registryAdrian R Hunt, Vuong Nguyen, Catherine P Creuzot-Garcher, et al.
Frontiers in Immunology|April 18, 2024
C-reactive protein-complement factor H axis as a biomarker of activity in early and intermediate age-related macular degenerationLena Giralt, Marc Figueras-Roca, Beatriz De Luis Eguileor, et al.
Pageof 3